Gloria Crockett, senior director of quality
Type: Employee Stories
Topic(s): Company Quality & Safety
Use of an exclusive human milk diet in preterm infants to lower healthcare costs – short-term and long-term perspectives
Type: Prolacta in the News
Topic(s): Cost Savings / Cost Effectiveness Long-Term Outcomes Pasteurization
Prolacta Bioscience provides update on latest SARS-CoV-2 data and continued safety of its human milk-based nutritional products
Type: Press Releases
Topic(s): Quality & Safety
Prolacta’s manufacturing team shines in 2020
Type: Employee Stories
Topic(s): Quality & Safety
Donor Stephanie
Type: Donor Stories
Topic(s): Tiny Treasures
Donor Abbie gives back
Type: Donor Stories
Topic(s): Tiny Treasures
Donor Jade
Type: Donor Stories
Topic(s): Tiny Treasures
Late-onset sepsis reduced in premature infants fed Prolacta’s 100% human milk-based fortifiers as part of an exclusive human milk diet
Type: Press Releases
Topic(s): Clinical Studies Clinical Studies on Prolact/Humavant CR Late-Onset Sepsis
Prolacta Bioscience fortifiers reduce risk of serious lung disease and hospital costs among premature infants, compared to cow milk-based fortifiers
Type: Press Releases
Topic(s): Bronchopulmonary Dysplasia (BPD)